AI Article Synopsis
- Plasma vitronectin levels were lower in chronic hepatitis C patients who didn't respond to interferon alpha treatment compared to those who did respond, but no difference was found between the two groups of responders.
- After treatment, vitronectin levels increased in all patient groups and were associated with albumin levels.
- The study indicates that low initial vitronectin levels may predict a weaker response to interferon therapy in chronic hepatitis C patients.
Article Abstract
Plasma vitronectin concentration was measured in 60 patients with chronic hepatitis C before and after interferon alpha treatment. The plasma pretreatment levels of vitronectin in the interferon non-responders was significantly lower than those in the interferon sustained and transient responders, but the levels were not different in the latter two groups. After interferon therapy, the plasma levels of vitronectin were significantly increased in all three groups, and they were correlated with the albumin levels. Absolute changes of plasma vitronectin before and after interferon treatment were significantly related to initial levels, but they were not related to those of albumin or alanine aminotransferase levels. The values of sensitivity and specificity for plasma vitronectin in the sustained responder and non-responder were 45% and 95% for each. These results suggest that chronic hepatitis C patients with low levels of plasma vitronectin may have a weak response in interferon therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0009-8981(96)06503-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New proteomic signatures in Alzheimer Disease identification and Mild Cognitive Impairment Classification.
Alzheimers Dement
December 2024
The Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, London, United Kingdom
Background: Emerging technologies and novel biomarker tools are transforming the field of Alzheimer’s disease, allowing for a more in‐depth exploration of biological mechanisms underpinning the disease aetio‐pathogenesis. In this context, there is growing recognition of the potential of plasma proteomics for AD risk assessment and disease characterization. On the other hand, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
View Article and Find Full Text PDFHemocompatibility of Albumin-Modified Magnetic Nanoparticles.
Int J Mol Sci
November 2024
Department of Chemical and Material Engineering, University of Alberta, Edmonton, AB T6G 1H9, Canada.
Article Synopsis
- - Kidney failure leads to the build-up of harmful substances, known as uremic toxins, in the blood, which can increase the risk of serious health issues in patients.
- - Standard hemodialysis is often ineffective at clearing certain uremic toxins due to their strong binding to serum albumin, prompting researchers to explore advanced technologies like iron oxide magnetic nanoparticles for improved removal.
- - Studies indicated that albumin-modified nanoparticles had better hemocompatibility and reduced clotting compared to unmodified ones, suggesting they may be more effective for safely clearing uremic toxins from the blood.
A Novel P-III Metalloproteinase from Venom Degrades Extracellular Matrix Proteins, Inhibits Platelet Aggregation, and Disrupts Endothelial Cell Adhesion via α5β1 Integrin Receptors to Arginine-Glycine-Aspartic Acid (RGD)-Containing Molecules.
Toxins (Basel)
November 2024
Laboratório de Matriz Extracelular e Biotecnologia de Venenos, Universidade Federal do Paraná, UFPR, Curitiba 81531-980, Brazil.
Article Synopsis
- Viperid snake venoms contain metalloproteinases like barnettlysin-III (Bar-III), which cause bleeding and disrupt blood clotting and tissue integrity in victims.
- Bar-III, a specific type of metalloproteinase, has been characterized in terms of its properties, including its activity being enhanced by calcium and inhibited by zinc, and its ability to degrade important blood and tissue proteins.
- The study also highlights Bar-III’s effects on platelets and endothelial cells, suggesting that it affects platelet aggregation and cell adhesion, providing insights that could lead to new treatments for snakebite envenomation.
Lung-Targeting Perylenediimide Nanocomposites for Efficient Therapy of Idiopathic Pulmonary Fibrosis.
Nano Lett
October 2024
Laboratory for NanoMedical Photonics, School of Basic Medical Science, Henan University, Kaifeng 475004, China.
Idiopathic pulmonary fibrosis, an idiopathic interstitial lung disease with high mortality, remains challenging to treat due to the lack of clinically approved lung-targeting drugs. Herein, we present PDIC-DPC, a perylenediimide derivative that exhibits superior lung-selective enrichment. PDIC-DPC forms nanocomposites with plasma proteins, including fibrinogen beta chain and vitronectin, which bind to pulmonary endothelial receptors for lung-specific accumulation.
View Article and Find Full Text PDFVitronectin Levels in the Plasma of Neuroblastoma Patients and Culture Media of 3D Models: A Prognostic Circulating Biomarker?
Int J Mol Sci
August 2024
Incliva Biomedical Health Research Institute, 46010 Valencia, Spain.
Vitronectin is a glycoprotein present in plasma and the extracellular matrix that is implicated in cell migration. The high amount of vitronectin found in neuroblastoma biopsies has been associated with poor prognosis. Moreover, increased vitronectin levels have been described in the plasma of patients with different cancers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!